FOLH1 and prostate cancer: To enhance the efficacy of anti-PSMA CAR T, Carl June’s group developed anti-PSMA CAR T cells armored with a dominant negative TGF-β receptor (CART-PSMA-TGFβRDN) and observed enhanced cytokine secretion, resistance to T cell exhaustion, and induction of tumor eradication in the prostate cancer mouse models [32].